Published in J Natl Cancer Inst on February 05, 1997
Smad4/DPC4-mediated tumor suppression through suppression of angiogenesis. Proc Natl Acad Sci U S A (2000) 1.64
Expresson of vascular endothelial growth factor, its receptors (FLT-1, KDR) and TSP-1 related to microvessel density and patient outcome in vertical growth phase melanomas. Am J Pathol (2001) 1.49
Effects of THBS3, SPARC and SPP1 expression on biological behavior and survival in patients with osteosarcoma. BMC Cancer (2006) 1.29
PPARalpha deficiency in inflammatory cells suppresses tumor growth. PLoS One (2007) 1.24
CD47: A Cell Surface Glycoprotein Which Regulates Multiple Functions of Hematopoietic Cells in Health and Disease. ISRN Hematol (2013) 1.16
Thrombospondin-1 gene expression affects survival and tumor spectrum of p53-deficient mice. Am J Pathol (2001) 1.15
Loss of p53 and acquisition of angiogenic microRNA profile are insufficient to facilitate progression of bladder urothelial carcinoma in situ to invasive carcinoma. J Biol Chem (2011) 1.14
Expression and prognostic significance of THBS1, Cyr61 and CTGF in esophageal squamous cell carcinoma. BMC Cancer (2009) 1.11
Matricellular proteins: a sticky affair with cancers. J Oncol (2012) 1.10
Thrombospondin 2 expression is correlated with inhibition of angiogenesis and metastasis of colon cancer. Br J Cancer (1999) 1.09
Androgenic dependence of exophytic tumor growth in a transgenic mouse model of bladder cancer: a role for thrombospondin-1. BMC Urol (2008) 1.08
Anti-angiogenic effects of resveratrol mediated by decreased VEGF and increased TSP1 expression in melanoma-endothelial cell co-culture. Angiogenesis (2010) 1.07
Role of myoepithelial cells in breast tumor progression. Front Biosci (Landmark Ed) (2010) 1.03
Angiogenesis in cancer of unknown primary: clinicopathological study of CD34, VEGF and TSP-1. BMC Cancer (2005) 1.02
Extracellular matrix proteins and tumor angiogenesis. J Oncol (2010) 0.97
Unfolded protein response is required in nu/nu mice microvasculature for treating breast tumor with tunicamycin. J Biol Chem (2011) 0.96
Molecular pathways in bladder cancer. Urol Res (2004) 0.95
Cytogenetic monoclonality in multifocal uroepithelial carcinomas: evidence of intraluminal tumour seeding. Br J Cancer (1999) 0.93
Thrombospondin-1 expression in urothelial carcinoma: prognostic significance and association with p53 alterations, tumour angiogenesis and extracellular matrix components. BMC Cancer (2006) 0.93
Angiogenin promotes tumoral growth and angiogenesis by regulating matrix metallopeptidase-2 expression via the ERK1/2 pathway. Oncogene (2014) 0.92
Thrombospondin-1 in urological cancer: pathological role, clinical significance, and therapeutic prospects. Int J Mol Sci (2013) 0.91
Expression of thrombospondin-1 and Ski are prognostic factors in advanced gastric cancer. Int J Clin Oncol (2010) 0.90
Tumour cell thrombospondin-1 regulates tumour cell adhesion and invasion through the urokinase plasminogen activator receptor. Br J Cancer (2000) 0.89
Expression profiling for bladder cancer: strategies to uncover prognostic factors. Expert Rev Anticancer Ther (2010) 0.88
The role of angiogenesis in prostate and other urologic cancers: a review. CMAJ (2001) 0.88
The role of thrombospondin 1 on intestinal inflammation and carcinogenesis. Biomark Insights (2008) 0.87
Beta1 integrin cytoplasmic variants differentially regulate expression of the antiangiogenic extracellular matrix protein thrombospondin 1. Cancer Res (2009) 0.85
Mechanisms of tumor angiogenesis and therapeutic implications: angiogenesis inhibitors. Clin Exp Metastasis (1999) 0.84
Valproic acid decreases urothelial cancer cell proliferation and induces thrombospondin-1 expression. BMC Urol (2012) 0.83
Molecular substratification of bladder cancer: moving towards individualized patient management. Ther Adv Urol (2016) 0.82
Expression of thrombospondin-1 is correlated with microvessel density in gastric carcinoma. Virchows Arch (2003) 0.81
Thrombospondin-1-derived 4N1K peptide expression is negatively associated with malignant aggressiveness and prognosis in urothelial carcinoma of the upper urinary tract. BMC Cancer (2012) 0.80
Immunosurveillance by antiangiogenesis: tumor growth arrest by T cell-derived thrombospondin-1. Cancer Res (2014) 0.79
Automatic quantification of microvessel density in urinary bladder carcinoma. Br J Cancer (1999) 0.79
Identification of TAX2 peptide as a new unpredicted anti-cancer agent. Oncotarget (2015) 0.79
Gene therapy for bladder cancer using E1B-55 kD-deleted adenovirus in combination with adenoviral vector encoding plasminogen kringles 1-5. Br J Cancer (2003) 0.78
Molecular targets and targeted therapies in bladder cancer management. World J Urol (2008) 0.78
TP53 Status is Associated with Thrombospondin1 Expression In vitro. Front Oncol (2013) 0.77
The role of structural extracellular matrix proteins in urothelial bladder cancer (review). Biomark Insights (2007) 0.77
Immunohistochemical study of thrombospondin and its receptors alpha root of beta 3 and CD36 in normal thyroid and in thyroid tumours. J Clin Pathol (1999) 0.77
Current status and perspective of antiangiogenic therapy for cancer: urinary cancer. Int J Clin Oncol (2006) 0.77
Expression and characterization of novel thrombospondin 1 type I repeat fusion proteins. Biochem J (2000) 0.76
Primed for cancer: Li Fraumeni Syndrome and the pre-cancerous niche. Ecancermedicalscience (2015) 0.76
Role of thrombospondin 1 in liver diseases. Hepatol Res (2016) 0.76
TSP-1-1223 A/G Polymorphism as a Potential Predictor of the Recurrence Risk of Bladder Cancer in a Chinese Population. Int J Genomics (2013) 0.76
Osteopontin and thrombospondin-1 play opposite roles in promoting tumor aggressiveness of primary resected non-small cell lung cancer. BMC Cancer (2016) 0.75
FGF7/FGFR2 signal promotes invasion and migration in human gastric cancer through upregulation of thrombospondin-1. Int J Oncol (2017) 0.75
Incorporating VEGF-targeted therapy in advanced urothelial cancer. Ther Adv Med Oncol (2016) 0.75
Development and clinical testing of individual immunoassays for the quantification of serum glycoproteins to diagnose prostate cancer. PLoS One (2017) 0.75
Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol (2001) 11.35
The DNA sequence and comparative analysis of human chromosome 20. Nature (2002) 7.40
The influence of margin width on local control of ductal carcinoma in situ of the breast. N Engl J Med (1999) 6.16
Prognostic factors in colorectal cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med (2000) 5.68
Mechanical work in terrestrial locomotion: two basic mechanisms for minimizing energy expenditure. Am J Physiol (1977) 4.79
The DNA sequence and analysis of human chromosome 6. Nature (2003) 4.75
Accumulation of nuclear p53 and tumor progression in bladder cancer. N Engl J Med (1994) 4.34
The distribution of muramidase (lysozyme) in human tissues. J Clin Pathol (1975) 4.03
National survey of doses from CT in the UK: 2003. Br J Radiol (2006) 4.01
Southern blot analysis of DNA extracted from formalin-fixed pathology specimens. Cancer Res (1986) 3.95
Muscular force in running turkeys: the economy of minimizing work. Science (1997) 3.45
Immunoperoxidase techniques: practical and theoretical aspects. Arch Pathol Lab Med (1978) 3.42
Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase. Clin Cancer Res (2000) 3.42
The demonstration of plasma cells and other immunoglobulin-containing cells in formalin-fixed, paraffin-embedded tissues using peroxidase-labelled antibody. J Clin Pathol (1974) 3.41
Concordance for Hodgkin's disease in identical twins suggesting genetic susceptibility to the young-adult form of the disease. N Engl J Med (1995) 3.31
High frequency of acute promyelocytic leukemia among Latinos with acute myeloid leukemia. Blood (1996) 3.24
Bioassay of prostate-specific antigen (PSA) using microcantilevers. Nat Biotechnol (2001) 3.12
Recommendations for the use of antiemetics: evidence-based, clinical practice guidelines. American Society of Clinical Oncology. J Clin Oncol (1999) 2.97
Energetics of running: a new perspective. Nature (1990) 2.96
ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy. J Clin Oncol (2001) 2.87
Spindle dynamics and the role of gamma-tubulin in early Caenorhabditis elegans embryos. Mol Biol Cell (2001) 2.87
Tissue-specific expression of a chicken calmodulin pseudogene lacking intervening sequences. Proc Natl Acad Sci U S A (1983) 2.86
Results with radical cystectomy for treating bladder cancer: a 'reference standard' for high-grade, invasive bladder cancer. BJU Int (2003) 2.78
A long-term follow-up study of survival in stage I (T1N0M0) and stage II (T1N1M0) breast carcinoma. J Clin Oncol (1989) 2.71
Ovomucoid intervening sequences specify functional domains and generate protein polymorphism. Cell (1980) 2.57
Diagnosis and management of renal cell carcinoma. A clinical and pathologic study of 309 cases. Cancer (1971) 2.56
The DNA sequence and biological annotation of human chromosome 1. Nature (2006) 2.42
Intracellular immunoglobulins. A comparative study on three standard tissue processing methods using horseradish peroxidase and fluorochrome conjugates. J Clin Pathol (1974) 2.36
ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy. J Clin Oncol (1998) 2.26
Energetics and mechanics of terrestrial locomotion. I. Metabolic energy consumption as a function of speed and body size in birds and mammals. J Exp Biol (1982) 2.25
Stenosis of the afferent antireflux valve in the Kock pouch continent urinary diversion: diagnosis and management. J Urol (1994) 2.24
In situ demonstration of T lymphocyte subsets in granulomatous inflammation: leprosy, rhinoscleroma and sarcoidosis. Clin Exp Immunol (1983) 2.21
Antithrombotic therapy in atrial fibrillation. Chest (1992) 2.21
Thymidylate synthase mRNA level in adenocarcinoma of the stomach: a predictor for primary tumor response and overall survival. J Clin Oncol (1996) 2.21
Detection and clinical importance of micrometastatic disease. J Natl Cancer Inst (1999) 2.21
Hospital admission and the start of benzodiazepine use. BMJ (1992) 2.20
Quantitation of intratumoral thymidylate synthase expression predicts for disseminated colorectal cancer response and resistance to protracted-infusion fluorouracil and weekly leucovorin. J Clin Oncol (1997) 2.19
Susceptibility of nonpromoter CpG islands to de novo methylation in normal and neoplastic cells. J Natl Cancer Inst (2001) 2.13
Antigen retrieval techniques: current perspectives. J Histochem Cytochem (2001) 2.11
Angiogenesis in bladder cancer: relationship between microvessel density and tumor prognosis. J Natl Cancer Inst (1995) 2.10
Antithrombotic therapy in atrial fibrillation. Chest (1995) 2.08
Orthotopic urinary diversion with preservation of erectile and ejaculatory function in men requiring radical cystectomy for nonurothelial malignancy: a new technique. J Urol (1999) 2.08
The role of radical cystectomy in the management of high grade superficial bladder cancer (PA, P1, PIS and P2) J Urol (1990) 2.07
Effect of p21WAF1/CIP1 expression on tumor progression in bladder cancer. J Natl Cancer Inst (1998) 2.07
Predictors and correlates of adaptive functioning in children with developmental disorders. J Autism Dev Disord (2001) 2.06
Contribution of the bronchial circulation to lung preservation. J Thorac Cardiovasc Surg (1991) 2.03
The chick ovomucoid gene contains at least six intervening sequences. Nature (1979) 2.01
A multivariate analysis of genomic polymorphisms: prediction of clinical outcome to 5-FU/oxaliplatin combination chemotherapy in refractory colorectal cancer. Br J Cancer (2004) 2.01
T lymphocyte subsets in the skin lesions of patients with leprosy. J Am Acad Dermatol (1983) 2.01
Pegylated liposomal doxorubicin (doxil): reduced clinical cardiotoxicity in patients reaching or exceeding cumulative doses of 500 mg/m2. Ann Oncol (2000) 2.00
Chicken calmodulin genes. A species comparison of cDNA sequences and isolation of a genomic clone. J Biol Chem (1983) 1.98
Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation. J Clin Oncol (1997) 1.97
Antigen retrieval immunohistochemistry: past, present, and future. J Histochem Cytochem (1997) 1.96
The nature of Reed-Sternberg cells and other malignant "reticulum" cells. Lancet (1974) 1.95
Is there a chiropractic science? J Manipulative Physiol Ther (1990) 1.94
Thymidylate synthase gene polymorphism determines response and toxicity of 5-FU chemotherapy. Pharmacogenomics J (2001) 1.93
Prevention of neonatal respiratory distress syndrome by tracheal instillation of surfactant: a randomized clinical trial. Pediatrics (1985) 1.92
Antigen retrieval technique utilizing citrate buffer or urea solution for immunohistochemical demonstration of androgen receptor in formalin-fixed paraffin sections. J Histochem Cytochem (1993) 1.91
Specific genetic analysis of microscopic tissue after selective ultraviolet radiation fractionation and the polymerase chain reaction. Am J Pathol (1992) 1.91
Two molecular pathways to transitional cell carcinoma of the bladder. Cancer Res (1994) 1.86
p53 nuclear protein accumulation correlates with mutations in the p53 gene, tumor grade, and stage in bladder cancer. Am J Pathol (1993) 1.85
Wood's light in dermatology. Int J Dermatol (1999) 1.84
Urodynamic findings in chronic retention of urine and their relevance to results of surgery. Br Med J (1978) 1.84
Factors influencing prognosis in node-negative breast carcinoma: analysis of 767 T1N0M0/T2N0M0 patients with long-term follow-up. J Clin Oncol (1993) 1.83
The role of adjuvant chemotherapy following cystectomy for invasive bladder cancer: a prospective comparative trial. J Urol (1991) 1.81
The concept of symmorphosis: a testable hypothesis of structure-function relationship. Proc Natl Acad Sci U S A (1991) 1.80
An immunohistological study of follicular lymphoma, reticulum cell sarcoma and Hodgkin's disease. Eur J Cancer (1976) 1.78
The immunohistological detection of intracellular immunoglobulin in formalin-paraffin sections from multiple myeloma and related conditions using the immunoperoxidase technique. Clin Exp Immunol (1974) 1.76
Design of the mammalian respiratory system. III Scaling maximum aerobic capacity to body mass: wild and domestic mammals. Respir Physiol (1981) 1.74
In situ identification of cells in human leprosy granulomas with monoclonal antibodies to interleukin 2 and its receptor. J Immunol (1984) 1.74
Medical student, resident, and faculty use of a computerized literature searching system. Bull Med Libr Assoc (1989) 1.72
A Xeroderma pigmentosum group D gene polymorphism predicts clinical outcome to platinum-based chemotherapy in patients with advanced colorectal cancer. Cancer Res (2001) 1.72
Complications of laparoscopic procedures after concentrated training in urological laparoscopy. J Urol (2001) 1.71
Generation of human monoclonal antibodies reactive with cellular antigens. Proc Natl Acad Sci U S A (1983) 1.71
DNA methylation profiles in diffuse large B-cell lymphoma and their relationship to gene expression status. Leukemia (2008) 1.70
Speed, stride frequency and energy cost per stride: how do they change with body size and gait? J Exp Biol (1988) 1.69
Energetics and mechanics of terrestrial locomotion. III. Energy changes of the centre of mass as a function of speed and body size in birds and mammals. J Exp Biol (1982) 1.69
High basal level gene expression of thymidine phosphorylase (platelet-derived endothelial cell growth factor) in colorectal tumors is associated with nonresponse to 5-fluorouracil. Clin Cancer Res (1998) 1.68
Molecular cloning of ovomucoid gene sequences from partially purified ovomucoid messenger RNA. Biochemistry (1978) 1.67